DIA

CALL FOR ABSTRACTS

SUBMISSION DEADLINE: THURSDAY, JUNE 1

DIA Annual Canadian Meeting

OCTOBER 16-18 | OTTAWA, ONTARIO, CANADA

Abstract Overview and Topics

The *DIA Annual Canadian Meeting* will reflect on the evolution of Canada's health system by bringing together key thought leaders from industry, academia, and regulatory, including Health Canada. Expert speakers will discuss in-depth how collaboration can support new regulatory processes (innovative, OTC, generic), innovation, access, as well as trends in clinical research and operations, and developing transparency and engagement initiatives.

We are accepting abstracts for 20 minute presentations (speakers), 90 minute sessions (chairs), and 3.5 hour pre-meeting short courses (instructors). When visiting the DIA website to submit your abstract, be sure to select the correct abstract type (presentation, session, or short courses). Topics may include, but are not limited to:

Generics

- Intellectual Property (IP) considerations
- Innovation in how policy is applied
- Innovation in manufacturing and supply chain management

Regulatory Processes

- How existing regulatory processes deal with innovative technologies
- What kinds of innovative regulatory processes have been developed to increase efficiency or to incentivize particular areas of product development (international experience, orphan drug framework)
- Novel approaches to existing regulatory challenges (enhanced collaboration or building common tools between regulatory authorities to address GMP compliance; work-sharing models)
- International regulatory processes
- OTC products—current and future landscape

Clinical Trial Design and Research

- Adaptive clinical trial design—application and effect on product life cycle
- How to appropriately choose endpoints that will meet regulator, payer, and HTA needs
- Surrogate endpoints
- Combination product clinical trial design
- Novel approaches in clinical trial recruitment
- Clinical trial data transparency
- Wearables in clinical trials
- Artificial intelligence and/or machine learning in clinical research

Patient Care/Patient Voice/Engagement

- Plain Language Labeling (PLL) – trend to more at home care versus institution care and how this affects labeling of drug products (that would be traditionally labeled for the Health Canada professional)
- Self-care markets, nonprescription products – when the patient is the one selecting the product, what considerations need to be made from various perspectives
- What are the roles of patient advocates and patient associations and how have they become a strong stakeholder in adding value to conversations at regulator, payer, international levels, etc.; how are patient associations included in conversations and how do patient associations want to be included in conversations?
- Mobile health products and services

Policy Development and Direction

- How to effectively collaborate and engage in policy, including collaborating with HC
- How to critically review draft health authority guidance documents

Transparency and Openness

- Amendments to the Food and Drugs Act
- Updates on transparency initiatives (phase 2)

Data Analytics/Real-World Data

Abstracts should focus on current application and analysis of Real-World Data, including:

- Data mining, surveillance, and analysis
- Using public databases

Personalized Medicine

- Screenings for diseases
  - Biomarker use in clinical trials
- Genetic testing
- Gene editing

Mobile Health and Social Media

- Best practices for social media use in patient engagement—compliance, legal, regulatory, and medical considerations
- Promotion and advertising in social media
- How to incorporate the patient voice – addressing the growing number of patient entry databases

Risk Communication

- Crisis management
- How to ensure regulatory message stays on point

Postmarket Perspective

Abstract Submission Deadline: Thursday, June 1
Notification: Mid- to Late-June
PowerPoint Presentations Due: Friday, September 22
Meeting Dates: October 16-18
Location: Ottawa, Ontario, Canada
Please Submit All Abstracts Online at DIAglobal.org/Abstracts

Submit Your Abstract at **DIAglobal.org/Abstracts**

CALL FOR ABSTRACTS

SUBMISSION DEADLINE: THURSDAY, JUNE 1

General Submission Requirements

(Please read the following instructions carefully; incorrect or incomplete abstracts will not be considered.)

1. All abstracts must be submitted online to **DIAglobal.org/Abstracts.**
2. Title must reflect the abstract content accurately and concisely.
3. Preference will be given to submitted abstracts that address real life applications and case studies.
4. Final PowerPoint presentation for all accepted abstracts will be due to DIA to be reviewed by the Committee and included on the DIA website for registered attendees. Should you choose to submit an abstract for consideration, please mark your calendars with the deadline.
5. Presentations should not overtly endorse or recommend a specific product or service. For-profit organizations or industry logos are no longer permitted to be included in slide presentations, per ACCME Standards for Commercial Support.
6. Time allotted for individual presentations will be approximately 15-20 minutes. Final timing will be determined by the session chair and based on the number of presentations selected for the session.
7. DIA will provide complimentary meeting attendance for the selected speaker.
8. Please note: Only one speaker per presentation will be allowed. Any exceptions to this policy must be discussed with the DIA office in advance.

Required Documentation for all abstracts

- **Participant Disclosure Information:** all abstract authors must disclose any relevant financial relationships with any commercial interest associated with this activity that exist or have existed within the past 12 months, as well as any discussion of unlabeled or unapproved drugs or devices. If you are proposing an abstract on behalf of the author, as the submitter you will not be asked to disclose. However, should the abstract be accepted, the author will be informed that he or she must complete and submit a Participant Disclosure in order to participate in the program.

- All submitters and authors must agree to the DIA Speaker Authorization for Use of Presentation Materials in order for the abstract to be a part of the Program. Accepted abstracts will be available on DIA's website for attendee download after the event.

SUBMISSION GUIDELINES *The following information will be requested at the time of submission.*

To streamline your submission process and avoid possible delays, DIA strongly encourages you to submit your abstract as early as possible. Do not wait until the last day.

Prepare your abstract in advance of accessing the DIA website. Abstract information should be copied and pasted from a prepared document as plain text. **All of the below fields are required.**

Author information The following information will need to be completed. NOTE: If you are submitting on behalf of the author, you are considered the SUBMITTER and will need to complete the required information for yourself AND also for the AUTHOR. Submitters will be the contact regarding the status of the abstract. If you are submitting your own abstract, you are considered the AUTHOR and will be the direct contact for this abstract.

Submitter or Author Information

Prefix:

First Name:

Middle Name:

Last Name:

Name Suffix:

Degrees:

Job Title:

Company:

Country:

Address Line:

City:

State/Province:

Zip/Postal Code:

Phone:

Email:

Abstracts will be reviewed, and authors will be notified of results by Mid- to Late-June

Abstract Title (maximum 125 characters, including spaces)
Titles should briefly describe the focus of the abstract as well as accurately reflect the content of the presentation.

Primary interest Area
Select the interest area that best relates to your abstract.

Keyword (Maximum 100 characters, including spaces)
One or more key words are to be provided to highlight your abstract. Examples of key words: Personalized Medicine, Health Technology Assessment, Clinical Trial Agreements.

Level of Difficulty (Select one)

Basic: Appropriate for individuals new to the topic/subject area.

Intermediate: Appropriate for individuals who already have a basic understanding of the topic/subject area.

Advanced: Appropriate for individuals with an in-depth knowledge of the topic/subject area.

Learning Objectives (maximum 400 characters, including spaces)
Please provide two to three learning objectives that clearly explain what participants should be able to do after attending this presentation. For a list of suggested verbs to create these objectives, please select the Learning Objectives link.

Method (Maximum 300 characters including spaces)
When, where, and how was the study done? What materials were used or who was included in the study?

Abstract Details (maximum 2,000 characters, including spaces)
Please provide complete details about your abstract. Information such as scientific, technical, process issues, design/methods, results/outcomes, case studies, statistics, key findings, etc., that would support your abstract should be included here. This information will be used by the Program Committee to learn more about the purpose of your abstract.